Pembrolizumab-induced myocarditis with complete atrioventricular block and concomitant myositis in a metastatic bladder cancer patient: a case report and review of the literature.
R SaadA GhaddarRony M ZeennyPublished in: Journal of medical case reports (2024)
Life-threatening cardiac adverse events in the form of myocarditis may occur with pembrolizumab use, warranting vigilant cardiac monitoring. Troponin monitoring in high-risk patients, along with baseline echocardiography may help identify this complication promptly to prevent life-threatening consequences.
Keyphrases
- left ventricular
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- advanced non small cell lung cancer
- squamous cell carcinoma
- small cell lung cancer
- computed tomography
- peritoneal dialysis
- prognostic factors
- case report
- heart failure
- rheumatoid arthritis
- diabetic rats
- patient reported outcomes
- interstitial lung disease
- systemic sclerosis
- endothelial cells
- idiopathic pulmonary fibrosis
- epidermal growth factor receptor